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Keywords:Several biobanking initiatives have emerged to create extensive collections of specimen for
biomedical studies and various analytical platforms. An affinity proteomic analysis with
antibody suspensionbeadarrayswas conducted to investigate the influenceof the pre-analytical
time and temperature conditions on blood derived samples. Serum and EDTA plasma prepared
from 16 individuals was centrifuged and aliquots were kept either at 4 °C or in ambient
temperature for 1 h and up to 36 h prior to first storage. Multiplexed protein profiles of post-
centrifugation delay were generated in 384 biotinylated samples using 373 antibodies that
targeted 343 unique proteins. Very few profiles were observed as significantly altered by the
studied temperature and time intervals. Single binder and sandwich assays revealed decreasing
levels of caldesmon 1 (CALD1) related to EDTA standard tubes and prolonged post-centrifugation
delay of 36 h. Indications from changes in CALD1 levels require further confirmation in
independent material, but the current data suggests that samples should preferentially be
frozen during the day of collection when to be profiled with antibody arrays selected for
this study.
Biological significance
Affinity-based profiling of serum and plasma by microarray assays can provide unique
opportunities for the discovery of biomarkers. It is though often not known how differences in
sample handling after collection influence the downstream analysis. By profiling three types
of blood preparations for alterations in protein profiles with respect to time and temperature
post centrifugation, we addressed an important component in the analysis and of such
specimen. We believe that this analysis adds valuable information to be considered when
biobanking blood derived samples.
This article is part of a Special Issue entitled: Standardization andQualityControl in Proteomics.
© 2013 The Authors. Published by Elsevier B.V. Open access under CC BY license.Affinity proteomics
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Over the recent years, biobanks have become more widely
recognized as an essential and valuable resource in medical
research. Prospective as well as retroprospective and high
quality samples are being collected within specific research
projects, routine health care or population cohorts. They
provide powerful tools for exploring the etiology of common
complex diseases, better understanding of the interplay
between genetic and lifestyle determinants and the develop-
ment of new diagnostic biomarkers and analytical methods.
Several large-scale population cohorts, such as UK Biobank
[1], Lifelines in the Netherlands and HUNT in Norway, are
pushing these frontiers further. As for all new prospective
biobanks, these studies have standard operations in place as
well as IT systems enabling a complete tracking of time and
temperature from needle to freezer. However, when utilizing
old sample collections, such as legacy samples, stored for
decades most of these samples have varying standards and
lack documentation on how samples have been collected,
processed and stored [2,3]. Success in identifying novel bio-
markers may well depend on variability in sampling handling
conditions between or within biobanks rather than disease
states. Uncertainty still remains to what extent and how
vulnerable differentmethodological approaches, such as the
emerging affinity proteomic technologies, are in this aspect
for their ability to discover and verify biomarkers.
For the widely used analysis based on mass spectrometric
determination of a target of interest, proteolytic activities or
other molecular modifications are important factors that alter
the experimental outcome, hence standardized collection and
handling procedures for proteomics [4] or metabolomics [5]
have become important factors in study designs. In anemerging
alternative to mass spectrometric analysis of proteins, namely
affinity proteomics, the use of reagents such as antibodies
is about to be established for a proteome-wide scale [6–8].
Alongside these efforts, technological advances have been
taking place, and regarding the analysis of serum and
plasma, the use of microarray technologies and the like are
often at the forefront [9]. Among the different types of protein
microarrays, the use of beads to create arrays in suspension
in combination with direct sample labeling offers an attrac-
tive platform to now screen larger sample collections with
up to 384 [10] or even 1728 antibodies per sample [11]. These
high throughput methodologies are well suited for unbiased
discovery proteomics, as they allow the analysis of many
samples at a time.
The purpose of this study was to investigate the extent
to which the pre-analytical phase between centrifuge and
freezer affects antibody-based plasma profiling. We analyzed
protein profiles generated by highly multiplexed single-
binder assays, and focused on serum and two types of
plasma collection tubes. A set of 16 healthy volunteers
donated blood at a single occasion and upon collection the
obtained specimens were handled differently from the time
of centrifugation until being frozen for storage. A linear
mixed model was used to assess each protein profile with
regard to time and/or temperature and alterations in vari-
ance across time per temperature were evaluated.2. Methods and material
2.1. Sample collection
Blood samples were collected from 16 donors, 8 males and 8
females in the age range 24–60 years. The study participants
were a group of volunteers, matched for age and gender and
were not diagnosed with a disease such as cancer or cardiovas-
cular disorder. The ethical review board in Stockholm, Sweden,
with giving consent by each participant, approved this study.
From each sample donor, a total volume of about 50-ml blood
was drawn into two 9-ml EDTA-Plasma Preparation Tube
(K2EDTA-PPT blood collection tubes: BD cat. no. 362799), two
9-ml EDTA standard (K2EDTA blood collection tubes: BD cat.
no. 367525) and two 9-ml serum venepuncture collection
tubes (Serum blood collection tubes: SST-tubes BD cat. no.
367953). The two sample types plasma (PL1) and serum (SER)
were thus prepared in three types of primary containers (PED ±
gel and SST), here described according to SPREC version 2.0 [12].
All samples were gently mixed for one min and the plasma
sampleswere centrifuged immediately at 2000 g for 10 minwhile
serumwas centrifuged within 40 min (SPREC; pre-centrifugation
delay A and centrifugation A). The sample collection tubes were
placed either in room temperature or at 4 °C. Plasma and serum
were then aliquoted in 100-μl fractions into 2D bar coded tubes
(REMP tubes in plate, SRBR-96-300, Brooks Life Science System) in
the time intervals 1, 3, 8 and 36 h after sample collection (SPREC;
post-centrifugation delay A-J) and stored at −80 °C until analysis
(SPREC; long-term storage Z) (Fig. 1). Twelve individuals were
included in the first phase of the study, while 16 individualswere
included for verification.
2.2. Antibodies
To build a 384-plex bead array, 364 affinity-purified rabbit
antibodies were selected from the Human Protein Atlas (HPA) [6]
and provided by Atlas Antibodies AB. Additionally, rabbit IgG
(Jackson ImmunoResearch Laboratories), albumin-binding pro-
tein (Affibody AB), anti-albumin antibody (rabbit IgG, Dako),
anti-KLK3 antibodies 1H12, 5A6, 8A6 (all mouse IgG, HyTest Ltd.),
anti-CNDP1 antibody AF2489 (goat IgG, R&D Systems), and
anti-CNDP1 3A6, 5B2, 8A3 (all mouse IgG, Atlas Antibodies AB)
were utilized. As summarized in Supplementary Table 1, 373 out
of 380 antibodies were unique and a total of 343 unique proteins
were targeted. The antibodies were selected based on their
protein targets classified as serum/plasma proteins, such as a
signal peptide predicting protein secretion, as well as in house
indications from other plasma biomarker projects, such as
Western blot analysis.
2.3. Bead coupling
Antibodieswere coupled to carboxylated beads (Luminex Corp.)
according to the manufacturer's protocol and as described
previously [10]. The coupling efficiency for each antibody was
determined via R-phycoerythrin-labeled anti-rabbit IgG anti-
body (Jackson ImmunoResearch Laboratories,) and a 383-plex
bead mixture, denoted antibody suspension bead array was
created as described previously [13]. A second coupling of 20 out
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Fig. 1 – Study overview. The figure provides an overview of sample collection and processing, assay workflow for the antibody
suspension bead array and the verification of the identified candidate protein. (Left panel) Blood samples from 16 individuals were
collected and serum and plasma (SER SST and PL1 PED ± gel) prepared and exposed to 4 °C or an ambient temperature
post-centrifugation for 1, 3, 8 and 36 h until final storage at −80 °C. (Center panel) Samples were transferred into a microtiter plate
format according to a randomized layout prior to direct labeling and subsequent heat treatment. After an overnight incubation with
the antibody suspension bead array andwash-step, a reportermoleculewas added and finally a flow cytometer like instrumentwith
a dual laser employed to detect captured proteins in conjunctionwith bead identity. (Right panel) The experimental strategy included
profiling of samples with both a single binder and sandwich assay.
48 J O U R N A L O F P R O T E O M I C S 9 5 ( 2 0 1 3 ) 4 6 – 5 4of 373 antibodies was performed to build a 20-plex bead array
applied in the initial verification stage.
2.4. Sample labeling and assay procedure
Three hundred and eighty four serum and plasma samples
(built from 288 unique samples) were labeled and analyzed in
accordance with previous studies [14] with minor changes. At
first, samples were thawed at RT, centrifuged for 10 min at
3000 rpm, and transferred into a microtiter plate (Abgene). The
plates were centrifuged (1 min at 3000 rpm), and 3 μl of each
sample was added to 22 μl of 1× PBS in four 96-well microtiter
plates with a liquid handler, according to a randomized layout
(TECAN, Freedom Evo 150). N-Hydroxysuccinimidyl ester of
biotinoyl tetraoxapentadecanoic acid (Pierce)was thenadded at
a 10-fold molar excess to yield an overall 1:10 sample dilution
followed by a 2-h incubation at 4 °C. The molar excess was
calculated based upon an approximate total protein content in
blood (60 mg/ml) and theoretical, average molecular weight of
70 kDa. A 10-foldmolar excess of biotin to protein in 1:10diluted
plasma was added in the labeling reaction. The reaction was
stopped by the addition of a 250-fold molar excess of Tris–HCl,
pH8.0 over biotin and incubated for another 20 min at 4 °C priorto a final storage at −80 °C. All samples were subsequently
utilized without removing unincorporated biotin and diluted
1:50 (CyBio, CyBi®-Selma) in an assay buffer composed of 0.5%
(w/v) polyvinyl alcohol and 0.8% (w/v) polyvinylpyrrolidone
(Sigma) in 0.1% casein in PBS supplemented with 0.5 mg/ml
rabbit IgG (Bethyl Laboratories). The samples were heat treated
in a thermocycler at 56 °C or 23 °C for 30 min; and 23 °C for
15 min. Then, 45 μl was combined with 5 μl of the 384-plexed
bead mixture in a 384-well flat bottomed half-area microtiter
plate (Greiner), and incubation took place overnight on a shaker
at anambient temperature. Beadswerewashed inwellswith 3×
100 μl of PBST (1× PBS, pH 7.4, 0.1% Tween20) (BioTek, EL406)
followed by 10 minwith 50 μl of a stop solution containing 0.1%
paraformaldehyde in PBS. Beads were washed, and 50 μl of
0.5 μg/ml R-phycoerythrin-labeled streptavidin (Invitrogen)
in PBST was added and incubated for 20 min. Finally, beads
were washed andmeasured in 100 μl of PBST (Luminex Corp.,
FlexMap3D).
2.5. Sandwich immunoassay
Crude, meaning neither diluted nor labeled plasma EDTA
standard samples were diluted 1:10 in assay buffer, combined
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was labeled with RPE conjugated Fab fragments anti-rabbit
IgG according to manufacturer's protocol (Z-25355, Molecular
Probes). Beads were washed and 50 μl 0.1 μg/ml labeled
detection antibody was added and incubated for 30 min.
Beads were washed followed by 10-min incubation with
stop solution. Finally, beads were washed and measured in
100 μl of PBST (Luminex Corp., LX200).
2.6. Study design
A total of 288 unique samples from 12 individuals (6 females + 6
males) and of three plasma or serum preparation types, exposed
to 4 °C or an ambient temperature with a post-centrifugation
delay of 1, 3, 8 and 36 h prior to freezingwere selected for the first
discovery phase. The shorter time intervals 1, 3 and 8 h were
focuseduponand themost extreme time interval 36h selected as
an endpoint. All samples were then randomized and distributed
across four 96-well plates for sample labeling and heat treatment
and transferred to one 384-well plate for the remainder of the
assay procedure. In addition, 24 sample poolswere created based
on sample preparation type and post centrifugation delay (time
and temperature) and used to assess the performance of the
assay in relation to the variability between the conditions. Thus
384 wells were analyzed. To assess reproducibility, 192 samples
were reanalyzed in a second, independent experiment. In the
verification phase, primary findings were verified by recoupling
antibodies of interest creating a second bead array utilized in
the reanalysis of the 384 samples. For further verification of a
finding, all 16 individuals' plasma EDTA standard samples
exposed to both temperatures for 3 or 36 h post-centrifugation
were analyzed (n = 64) with a 20-plex single binder assay
and secondly a sandwich immunoassay. In order to judge the
selectivity of the anti-CALD1 antibody HPA017330, 24 plasma
samples were analyzed with a 20-plex bead array including
HPA017330 for target capture and labeled HPA017330 for target
detection.
2.7. Data analysis
For each bead identity a minimal of 20 events was used as a
threshold to qualify the median fluorescence intensity (MFI)
for further analysis. The MFI values were processed per
sample preparation type. The first step was a distance based
outlier removal based on z score distribution, with z-value
>1.5 × interquartile range per sample group and antibody as
cut-off. It was followed by probabilistic quotient normalization
[15] for each sample plate as previously described [16]. The
deviation between the plates in a blood sample preparation
type was adjusted using multidimensional MA-normalization
assuming that the mean of samples within a plate is same for
all plates (nMFI) [17]. Finally, the pre-processed values were
log-transformed. The intensity differences across sample
groups divided by handling temperature and time were tested
with linear mixed effects model (LMM) [18], in which two
models estimating the fixed effects of 1) time and 2) the
interaction of time and temperature and both variables were
compared for each antibody. The time was the converted
integers from 1 to 4 for 1, 3, 8, or 36 h, respectively in order to
decrease the dominant effect of 36-h group. For bothmodels, thedonor ID is modeled as a random effect accounting for the
dependence of samples of the same human subject. Among
the two, the model with higher significance was selected.
Thehomogeneityof varianceacross groups separatedbyexposed
time in each handling temperature was tested with Bartlett's
method [19]. The overall variability within repeated analysis of
certain condition combination was calculated as the median of
the coefficient of variation (CV, ratio of standard deviation and
mean) for each protein profile.
Fold changes between samples were calculated from mean
intensities per antibody and log-2 transformed for the compar-
ison of blood sample preparation types serum and plasma.
We used false-discovery rate (FDR) corrected p-values from
Wilcoxon rank-sum test to determine sample preparation
dependant protein profiles and FDR from LMM and
Bartlett's test to determine which profiles were altered due
to handling conditions. For single-plexed experimental verifi-
cation, unadjusted p-values fromWilcoxon rank-sum test were
used. All data processing and analysis were conducted using
the R environment [20].3. Results
The study was designed to determine whether differences in
time and temperature during the period after centrifugation
and until the first freezing of samples would influence protein
profiles in serum and plasma samples. Serum and two types of
plasma preparations were collected from twelve individuals
and processed in accordance to the scheme shown in Fig. 1.
Here, the collected specimens were placed at either room
temperature or +4 °C for 1, 3, 8, or 36 h after centrifugation. All
sampleswere then frozen at −80 °C and thawed directly prior to
the processing involving direct sample labeling. Suspension
bead arrays were used to create protein profiles for 373
antibodies in 96 samples per sample preparation type.
At first, the distributions of profile intensity for the three
sample preparation types, collected in serum, EDTA standard
plasma and EDTA plasma preparation tubes (PPT) were com-
pared using the median value. While the intensity spread was
found to be narrower and of higher intensity for serum samples
than the two plasma samples (Fig. 2A–C), the two plasma sample
types revealed concordant intensity distributions. The variability
in protein profiles was assessed for the three preparation types,
each represented by eight sample pools that were created based
on conditions of the post-centrifugation delay period. As the
analysis of triplicated samples in Fig. 2D shows, the variability
was not changing neither for any of the investigated centrifuge-
to-freezer condition nor for the sample preparation types. When
comparing coefficients of variation (CV) collected for all
antibodies and sample preparation types, there was a
consistently higher CV between different samples than within
sample replicates. Sample profiles from replicated measure-
ments of 192 samples correlatedwith amedian r = 0.95 (0.8–1.0)
(Supplementary Fig. 1A). We then used 373 HPA antibodies
targeting 343 unique proteins to discriminate between serum
and plasma EDTA PPT or plasma EDTA standard tube samples.
As already indicated above, a majority (86%) of the protein
profiles in serum were at a higher intensity level than both
plasma types (322 out of 373 antibodies). As listed in Table 1, the
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Fig. 2 – Global data analysis. (A–C) The distributions ofmedian intensity per antibody and preparation types (A) serum, (B) EDTA PPT
and (C) EDTA standard are shown. (D) The variances in antibody profiles determined within a sample post-centrifugation condition
are shownacross replicates (grayboxes) andacrossdifferent samples (white boxes) for the threepreparation types. Sample replicates
were derived from pools of 24 samples and the variation was calculated from the coefficients of variation (CV).
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profiles' intensity fold change (absolute value) and FDR –
were however linked to plasma and exemplified by two
antibodies directed towards the known plasma protein
fibrinogen (FGB). A subset of the antibody selection (n = 18)
had previously been included in an analysis comparing
serum and plasma with antibody suspension bead arrays
[21] and besides two, all antibody-generated profiles were
concordant with respect to sample type associated intensity
difference and a statistical significance level FDR < 1 × 10−02.
In addition, the two plasma preparation types used in the studyTable 1 – Sample type discriminating profiles. Univariate Wilc
from the sample preparation types serum, plasma EDTA PPT a
proteins) with an absolute fold change ≥1.3 discriminated betw
proteins are classified as a secreted protein.
Antibdoy ID Gene name Uniprot ID Serum vs. EDTA
Fold change q-
HPA001901 FGB P02675 −3.6 1.2
HPA001900 FGB P02675 −3.5 1.8
HPA008356 RET P07949 −3.3 4.0
HPA016004 CHST8 Q9H2A9 −3.2 5.1
HPA035596 TRH P20396 −2.5 8.2
HPA030867 ADAM12 O43184 −2.5 3.7
HPA008549 SLC22A2 O15244 −1.7 7.0
HPA017737 PI3 P19957 1.4 4.9
HPA008791 MYBL1 P10243 1.7 3.4
HPA003873 LTB4R Q15722 2.2 1.2were compared. Here only one antibody, which targeted
caldesmon 1 (HPA017330), was found to reveal a differential
profile with higher intensity levels in EDTA standard compared
to EDTA PPT plasma preparation.
We then investigated the effect of differential temperature
and time during the post-centrifugation delay period on protein
profiles. Among the 343 unique proteins selected for this study,
itwas found that themost susceptible profile to a centrifuge-to-
freezer condition, indicated by a compromised intensity profile,
was for HPA017330 and decreased after the 8-h time interval
(Fig. 3). It's target protein is caldesmon 1 (CALD1) and in theoxon rank-sum tests were performed to compare profiles
nd plasma EDTA standard. Ten antibodies (targeting 9
een plasma and serum with FDR ≤ 1 × 10−24. Six of the nine
PPT Serum vs. EDTA
standard
EDTA PPT vs. EDTA
Standard
value Fold change q-value Fold change q-value
E-27 −3.5 4.8E-28 0.1 4.1E-01
E-27 −3.5 3.8E-29 0.0 8.6E-01
E-29 −3.3 5.3E-30 0.0 7.4E-01
E-29 −3.2 3.7E-30 0.0 9.1E-01
E-29 −2.5 5.5E-30 0.0 9.9E-01
E-29 −2.5 9.5E-31 −0.1 9.1E-01
E-28 −1.7 7.7E-30 −0.1 7.4E-01
E-24 1.4 6.0E-25 0.0 5.2E-01
E-29 1.7 4.0E-30 0.0 9.7E-01
E-28 2.0 1.1E-29 −0.1 3.8E-01
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a significant decrease (FDR = 3 × 10−03, slope = −0.14) in plasma
EDTA standard samples (Fig. 3A). The trend was verified in a
repeated experiment using the same samples and FDR =
8 × 10−03 was achieved. For EDTA PPT collection tubes a
similar, but statistically not significant trend was observed
(LMM p = 6 × 10−03, FDR = 8 × 10−01, slope = −0.07). Further
to this, four individuals were added to the analyses to supple-
ment the previously employed samples from 12 individuals in
order to be profiled for CALD1. Samples exposed to 4 °C or an
ambient temperature were combined to represent 3-h or 36-h
exposure time. First, the single binder assay revealed a difference
between the two groups of p = 1 × 10−03 (unadjusted). Then, a
dual binder sandwich assay (Fig. 3C) was conducted and
revealed a p-value = 6 × 10−03 to confirm that significantly
lowered CALD1 levels were found in samples left for 36 h
compared to 3 h. The latter assay was repeated as well and
the two intensity profiles correlated with Pearson's correlation
coefficient r = 0.93 (Fig. 3D). Furthermore, these sandwich immu-
noassays were performed together with 19 other antibodies to
evaluate theHPA017330 as detection antibody.While anti-CALD1
revealed MFI levels of ±150 AU, all other captured antibodies
showed 3-fold lower MFI levels (MFI ± 50 AU; Supplementary Fig.
2). This supports the previous observation that the antibody1 3 8 36
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were used to protein profile biotinylated serum and plasma
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sites of collection to central storage locations may still represent
an economically and logistically interesting scenario worth
considering.
There is a great value in biobanked samples providing
contemporary biomarker discovery efforts with constantly
growing numbers of specimen. However, various standards
and lack of documentation on how samples have been collected
and processed is a generalweakness of all biobanks, which limits
the possibility to utilize its' full potential. Since this variation
potentially could have a great impact on the results of down-
stream analysis there is a need to define a minimum level of
standard operation procedures for samples and for information
linked to the sample. In order to utilize the full potential of
archived samples inmedical research and to combine thesewith
newly collected material it is crucial to have information about
pre-analytical factors that might compromise the sample integ-
rity. Alternatively, it would be necessary to identify proteins that
are significantly influenced by variation in sample handling that
can qualify as marker candidates of biobank sample integrity.
With proteins in mind, alteration in profiles could be derived
by proteolytic degradation, complex formation, precipitation, or
even denaturation. Hemolysis, degree of coagulation or coagula-
tion inhibition as well as the depletion of hematopoietic cells
also influence the integrity of samples. Ideally, changes inprotein
profiles should be determined to estimate the extent of degrada-
tion and whether a certain archived biobank material can be
used in a particular analysis method. The results we presented
for CALD1 in this study cohort may provide first indications of
such a scenario. And also that it could be possible to find other
protein profiles that are linked to variations in sample handling
in all pre-analytical steps from needle to freezers, such as pre-
centrifugation or post-centrifugation delay.
In this study,we for instanceobserved that 86%of the targeted
proteinsweredetectedat ahigher intensity level in serumthan in
either plasma preparation type. This observation may be
supported by an affinity proteomics study, where a longer
storage time before centrifugationwas associated with increased
levels of inflammatory markers in serum, more so than plasma
[22]. Furthermore, mass spectrometry has previously identified
differential proteinprofiles of serumandplasmaaswell as serum
or plasma collection tube types [23]. The profile for an antibody
raised against caldesmon 1 (CALD1) was sensitive to handling
conditions in EDTA standard plasma, both using the discovery
driven single antibody assay as well as sandwich assays. The
same but not significant trendwas observed in profiles generated
in EDTA PPT collection tubes. The plasma PPT and serum tubes
contain a gel plug that physically separates cells from plasma
during centrifugation to facilitate improvedhandling.Our current
observation is that it could be likely that such a plug might have
prevented leakage of proteins fromblood cells and therebymight
have minimized the effect. For the presented study, it is also
noteworthy to mention that even though samples from only a
small number of individuals were included, all samples were
collected at one location and handled by a few people. This
reduced the impact of having different locations and operators
but suggested to extend later studies of this design across several
collection sites and personal. A success factor for biobanks is
therefore to use standardized protocol and full documentation of
all steps in the pre-analytical chain at locations of collection,distribution and storage, as well as documenting the subsequent
sample handling history at sites of analysis [24,25].
Themethod applied in the presented study is based on direct
labeling of the proteins in the samples followed by a heat
treatment step to retrieve epitopes [26] and the analysis in single
binder assays. Even though no analytical detection limits were
available for the included antibodies, the semi-quantitative
information obtained from the comparative analysis still
allows revealing putative changes in protein profiles. While
the discovery of only one profile could potentially also indicate
a lack in sensitivity or specificity, similar findings weremade in
a previous study, which employed a different class of affinity
reagents (aptamers) and investigated the impact based on pre-
and post-sample centrifugation handling times [27]. Concor-
dant results were also recently described for mass spectromet-
ric methods, where the a priori selection of targets of interest is
not necessarily generally required [4,28]. In the presented study,
affinity-purified polyclonal antibodies were applied for protein
profiling. These antibodies show oligo-epitopic target recogni-
tion [29] and their ability to detect a respective protein may for
this reason be partially less sensitive to protein degradation
than an analysis based on defined peptides. This could on the
other hand also be viewed as an advantage of these antibodies
when screening for differential protein profiles in across many
samples in a comparison of healthy and diseased individuals. As
alsomentionedabove, proteindenaturationor aggregationmight
occur during sample handling and this is however expected
to effect protein detectability, as the accessibility of the target
epitope(s) is reduced. We have observed this in another context
of a previous study, where intensity levels of most antibodies
decreased when samples had been heated to 96 °C prior to
analysis [26].
The protein identified as being susceptible to prolonged post-
centrifugationdelaywas caldesmon1 (CALD1). The protein exists
in distinct isoforms and is expressed as a high molecular weight
variant (h-CALD1) predominantly in smooth muscle. The low
molecular weight isoforms lack a central repeated domain of
h-CALD1 but are expressed in non-muscle tissues and cells and
have previously been described as glioma marker in serum [30].
CALD1 binds Ca(2+)-calmodulin, actin, tropomyosin, myosin,
andphospholipids andhas an essential role in regulating smooth
muscle and non-muscle actomyosin interactions as well as
cell motility functions [31]. The anti-CALD1 antibody HPA017330
had been raised against a 132-residue long fragment, matched
to most splice variants and all isoforms (Supplementary Fig. 3).
It stained cytoplasmic expression in smooth muscle,
myoepithelial cells, endothelium, ovarian and endometrial
stroma in immunohistochemistry and subcellular staining
was localized to actin filaments and the plasma membrane
[http://www.proteinatlas.org/ENSG00000122786]. Other anti-
CALD1 antibodies have confirmed these staining patterns but
did not qualify for plasma analysis due to concentration or
formulation. Further evidence for the single binder CALD1
profilewas achieved using a dual binder assay,whereHPA017330
was used for both capture and detection. A current, yet
speculative explanation for the alteration of the CALD1 profiles
is that the prolonged incubation in EDTA leads to extensive
calcium ion chelation where Ca-binding proteins and their
associated binding partners may precipitate. Nevertheless,
additional experimental evidence using mass spectrometry or
53J O U R N A L O F P R O T E O M I C S 9 5 ( 2 0 1 3 ) 4 6 – 5 4othermeans of detection, and evenmanymore samples as well
as an optimized immunoassay enabling an improved discrim-
inative power would be needed to establish more the current
indications from CALD1 decrease in EDTA plasma could
become a useful indicator for handling variability for already
biobanked samples as well as for samples being collected.
Biobanks aim to serve as a dynamic resource for research
today and long into the future perhaps with technologies
we cannot yet predict. Many samples will though/however be
stored for decades and in some biobanks risk repeated freeze-
thaw-cycles, for example during rounds of aliquotation and
withdrawal. At this point our study does not provide evidence if
certain processing conditions prior to sample freezing could
trigger processes that lead tomore substantial changes in profiles
thanwe observed. Even though this goes beyond the scope of our
study asweonly lookedat samples being stored for a short period
and transferred in one shipped, sample profiles from long-term
storage and freeze/thaw cycles should also be investigated.
Nevertheless, the made observations should be considered
when aiming at improving study design for antibody array
analysis or othermethodologies that aim to conduct biomarker
discovery studies in serum and plasma.
In conclusion, our study shows that the protein profiles
generated in directly labeled serum and plasma and by antibody
bead arrays appeared generally not compromised by time and
temperature conditions post-centrifugation and prior to storage.
This is in good agreement with observations made for mass
spectrometry [4] and alternative protein scaffolds [27]. The
presented work therefore provides a perspective on post
centrifugation delay in the analysis of blood-derived samples
when choosingmultiplexed and affinity based assays to profile
proteins.
Supplementary data to this article can be found online at
http://dx.doi.org/10.1016/j.jprot.2013.04.020.Acknowledgment
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